聚乙二醇干扰素α-2a联合拉米夫定或阿德福韦治疗乙型肝炎e抗原阳性慢性乙型肝炎96周疗效观察被引量：8

导出

摘要核苷（酸）类药物（NA）和干扰素在抑制HBV复制、延缓疾病进展等方面起到重要作用。但NA治疗后HBeAg血清学转换率较低，长期应用容易引发耐药；干扰素治疗后HBeAg血清学转换率相对较高，但总体转换率尚不足1／3，特别是HBsAg清除率较低。因此，探索优化治疗方案非常必要。NA和干扰素的作用靶位和作用机制不同，联合使用可能产生互补或相加作用。

作者曹振环柳雅立马丽娜鲁俊锋金怡何智敏陈新月

机构地区首都医科大学附属北京佑安医院肝病综合科

出处《中华传染病杂志》 CAS CSCD 北大核心 2016年第7期422-424,共3页 Chinese Journal of Infectious Diseases

基金国家“十二五”科技重大专项（013ZX10002002-006）首都临床特色应用研究（Z151100004015181）佑安肝病艾滋病基金院内中青年人才孵育项目（YNKT20160021）

关键词聚乙二醇干扰素Α-2A 治疗方案慢性乙型肝炎 E抗原阳性疗效观察阿德福韦拉米夫定 HBEAG

分类号 R512.62 [医药卫生—内科学]

引文网络
相关文献

参考文献8

1Sonneveld MJ, Janssen HL. Pros and cons of peginterferon versus nucleos (t) ide analogues for treatment of chronic hepatitisB[J]. Curr HepatRep, 2010,9(2):91 98. DOI:10. 1007/s11901 010-0041-7.
2Marcellin P, Heathcote EJ, Buti M,et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B [J].N Engl J Med, 2008,359 (23):2442-2455. DOI: 10. 1056/ NEJMoa0802878.
3Lau GKK, Piratvisuth T, Luo KX, et al. Durability of response and occurrence of late response to peginterferon alfa 2a (40KD) [PEGASYS] one year post- treatment in patients with HBeAg- positive chronic hepatitis B [J]. J Hepatol, 2006,44(Suppl 2):S23-24.
4Niederau C, Heintges T, Lange S, et al. Long-term follow up of HBeAg positive patients treated with interferon alfa for chronic hepatitis B [J]. N Engl J Med, 1996, 334(22): 1422- 1427. DOI: 10. 1056/NEJM199605303342202.
5Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with laegimerferon alpha-2b [J]. Gastroenterology, 2008,135(2) : 459-467. DOI:10. 1053/j. gastro. 2008.05. 031.
6Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B [J]. N Engl J Med, 2004,351(12) : 1206-1217. DOI: 10. 1056/NEJMoa040431.
7Marcel/in P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a[J]. Gastroenterology, 2009,136 (7) :2169-2179. DOI:10. 1053/j. gastro. 2009.03. 006.
8Invited Abstract: 19 (th) Conference of the Asian Pacific Association for the Study of the Liver [J]. Hepatol Int, 2009, 3(1) :1-23, DOI:10. 1007/s12072-008-9119-5.